Literature DB >> 6747817

Pharmacokinetics of quinidine and three of its metabolites in man.

A Rakhit, N H Holford, T W Guentert, K Maloney, S Riegelman.   

Abstract

Disposition parameters of quinidine and three of its metabolism, 3-hydroxy quinidine, quinidine N-oxide, and quinidine 10,11-dihydrodiol, were determined in five normal healthy volunteers after prolonged intravenous infusion and multiple oral doses. The plasma concentrations of individual metabolites after 7 hr of constant quinidine infusion at a plasma quinidine level of 2.9 +/- (SD) 0.3 mg/L were: 3-hydroxy quinidine, 0.32 +/- 0.06 mg/L; quinidine N-oxide, 0.28 +/- 0.03 mg/L; and quinidine 10,11-dihydrodiol, 0.13 +/- 0.04 mg/L. Plasma trough levels after 12 oral doses of quinidine sulfate every 4 hr averaged: quinidine, 2.89 +/- 0.50 mg/L; 3-hydroxy quinidine, 0.83 +/- 0.36 mg/L; quinidine N-oxide, 0.40 +/- 0.13 mg/L; and quinidine 10,11-dihydrodiol, 0.38 +/- 0.08 mg/L. Relatively higher plasma concentrations of 3-hydroxy quinidine metabolite after oral dosing probably reflect first-pass formation of this quinidine metabolite. A two-compartment model for quinidine and a one-compartment model for each of the metabolites described the plasma concentration-time curves for both i.v. infusion and multiple oral doses. Mean (+/- SD) disposition parameters for quinidine from individual fits, after i.v. infusion were as follows: Vl, 0.37 +/- 0.09 L/kg; lambda 1, 0.094 +/- 0.009 min-1; lambda 2, 0.0015 +/- 0.0002 min-1; EX2, 0.013 +/- 0.002 min-1; clearance (ClQ), 3.86 +/- 0.83 ml/min/kg. Both plasma and urinary data were used to determine metabolic disposition parameters. Mean (+/- SD) values for the metabolites after i.v. quinidine infusion were as follows: 3-hydroxy quinidine: formation rate constant kmf, 0.0012 +/- 0.0005 min-1, volume of distribution, Vm, 0.99 +/- 0.47 L/kg; and elimination rate constant, kmu 0.0030 +/- 0.0002 min-1. Quinidine N-oxide: kmf, 0.00012 +/- 0.00003 min-1; Vm, 0.068 +/- 0.020 L/kg; and kmu, 0.0063 +/- 0.0008 min-1. Quinidine 10,11-dihydrodiol: kmf, 0.0003 +/- 0.0001 min-1; Vm, 0.43 +/- 0.29 L/kg; and kmu, 0.0059 +/- 0.0010 min-1. Oral absorption of quinidine was described by a zero order process with a bioavailability of 0.78. Concentration dependent renal elimination of 3-hydroxy quinidine was observed in two out of five subjects studied.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6747817     DOI: 10.1007/BF01063608

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  11 in total

1.  The PROPHET system and resource sharing.

Authors:  W F Raub
Journal:  Fed Proc       Date:  1974-12

2.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

3.  Prevalence of high (3S)-3-hydroxyquinidine/quinidine ratios in serum, and clearance of quinidine in cardiac patients with age.

Authors:  D E Drayer; M Hughes; B Lorenzo; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

4.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

5.  Absolute quinidine bioavailability.

Authors:  C T Ueda; B J Williamson; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

6.  Assignment of conformation and configuration to potassium permanganate oxidation products of quinidine.

Authors:  Y Yanuka; S Yosselson-Superstine; A Geryes; E Superstine
Journal:  J Pharm Sci       Date:  1981-06       Impact factor: 3.534

7.  Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function.

Authors:  D E Drayer; D T Lowenthal; K M Restivo; A Schwartz; C E Cook; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

8.  Isolation, characterisation and synthesis of a new quinidine metabolite.

Authors:  T W Guentert; J J Daly; S Riegelman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

9.  Improved liquid-chromatographic assay of quinidine and its metabolites in biological fluids.

Authors:  A Rakhit; M Kunitani; N H Holford; S Riegelman
Journal:  Clin Chem       Date:  1982-07       Impact factor: 8.327

10.  Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.

Authors:  T W Guentert; N H Holford; P E Coates; R A Upton; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-08
View more
  9 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Population pharmacokinetics of quinidine.

Authors:  K Fattinger; S Vozeh; H R Ha; M Borner; F Follath
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors:  P Veng-Pedersen; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

5.  The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

Authors:  R A Wooding-Scott; J Smalley; J Visco; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

6.  Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.

Authors:  W R Gillespie; P Veng-Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1985-08

7.  Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs.

Authors:  A Rakhit; T W Guentert; N H Holford; J Verhoeven; S Riegelman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

8.  pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.

Authors:  Sibylle Neuhoff; Anna-Lena Ungell; Ismael Zamora; Per Artursson
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

9.  Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

Authors:  K Brøsen; F Davidsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.